William Fitzsimmons

Dr. William Fitzsimmons


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
AKAmanda Klein
Amanda Klein
ALAlexandre Loupy
Alexandre Loupy
MSMark Stegall
Mark Stegall
IHIlkka Helanterä
Ilkka Helanterä
LKLuke Kosinski
Luke Kosinski
WFWilliam Fitzsimmons
William Fitzsimmons
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.

24 December 2021 in Transplantation
Verified
Journal Article
Open access
JEJay Erdman
Jay Erdman
JWJosephine Ma Wolfram
Josephine Ma Wolfram
DNDavid MPH Nimke
David MPH Nimke
RCRichard Ma Croy
Richard Ma Croy
XWXuegong Wang
Xuegong Wang
WFWilliam Fitzsimmons
William Fitzsimmons
Background.: The Scientific Registry of Transplant Recipients was retrospectively analyzed to provide real-world evidence of the efficacy and safety of tacrolimus-based immunosuppressive regimens in adult lung transplant recipients in the United States. Methods.: Adult recipients (N = 25 355; ≥18 y) of a primary deceased-donor lung transplant between January 1, 1999, and December 31, 2017, were followed for 3 y posttransplant based on immunosuppressive regimen at discharge: immediate-release tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), cyclosporine (CsA) + MMF, or CsA + AZA. The primary outcome was the composite endpoint of graft failure or death (all-cause) at 1 y posttransplant (calculated via a modified Kaplan–Meier method). Results.: Discharge immunosuppressive regimens in lung transplant recipients changed over time, with a substantial increase in the use of TAC + MMF. TAC + MMF was the most common immunosuppressive regimen (received by 61.0% of individuals at discharge). The cumulative incidence of graft failure or death at 1 y posttransplant in adult lung transplant patients receiving TAC + MMF was 8.6% (95% confidence interval 8.1-9.1). Risk of graft failure or death was significantly higher in adults receiving CsA + MMF or CsA + AZA compared with TAC + MMF, with no significant difference seen between TAC + MMF and TAC + AZA. TAC + MMF had the highest continued use at 1 y posttransplant (72.0% versus 35.4%–51.5% for the other regimens). There was no increase in the rate of infection or malignancy in the TAC + MMF group. Conclusions.: Real-world evidence from the most comprehensive database of transplant recipients in the United States supports the use of TAC in combination with MMF or AZA as maintenance immunosuppression in adult lung transplant recipients.

29 July 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
DTDavid J. Taber
David J. Taber
EGElisa J. Gordon
Elisa J. Gordon
LMLarissa Myaskovsky
Larissa Myaskovsky
MJMichelle T. Jesse
Michelle T. Jesse
JPJohn Devin Peipert
John Devin Peipert
JGJohn S. Gill
John S. Gill
AST commissioned a survey assessing transplant recipients' perceptions of unmet immunosuppressant needs. Topics included medication side-effects, treatment burden, health-related quality of life (HRQoL), adherence, self-efficacy, costs, trust, and discrimination; 10,091 responses were included (9,543 adults, 548 pediatrics) representing 232 transplant centers. Respondents were a mean of 6.6 years post-transplant, and were well represented across age, sex, race, ethnicity, organ, employment, insurance, and immunosuppression. Nearly all (92%) respondents reported at least one side-effect (median of 3); most side-effects occurred 'often' or 'always'. The majority (54%) of side-effects were rated as having a 'moderate' or 'great deal' of impact on daily life. Side effects with the greatest daily burden included skin cancer, pain/neuropathy, skin issues, kidney disease, memory/brain fog, diabetes, cancer, and hypertension. Fatigue, headache, insomnia, tremors, and mood/depression/anxiety were the most selected side-effects. HRQoL was rated as 'fair' to 'good'. Trust in providers, self-efficacy, and medication adherence were rated highly, though 25% reported skipping doses due to side-effects, and 40% skipped due to costs. Findings demonstrate that side-effects are nearly universally experienced and have a major burden on daily life. Immunosuppression induces a heavy toll on transplant recipients; there is urgent need for new treatments to address these unmet needs.

18 April 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AKAmanda Klein
Amanda Klein
LKLuke Kosinski
Luke Kosinski
ALAlexandre Loupy
Alexandre Loupy
EFEric Frey
Eric Frey
MSMark Stegall
Mark Stegall
WFWilliam Fitzsimmons
William Fitzsimmons
Biopsy-proven acute rejection (BPAR) occurs in approximately 10% of kidney transplant recipients in the first year making superiority trials unfeasible. IBOX, a quantitative composite of eGFR, proteinuria, anti-HLA DSA, and + full/- abbreviated kidney histopathology, is a new proposed surrogate endpoint. BPAR's prognostic ability was compared to iBOX in a pooled cohort of 1534 kidney transplant recipients from four datasets, including two prospective randomized controlled trials. Discrimination analyses showed mean c-statistic differences between both iBOX compared to BPAR of 0.25 (95%CI: 0.17, 0.32) for full iBOX and 0.24 (95%CI: 0.16, 0.32) for abbreviated iBOX, indicating statistically significantly higher c-statistic values for the iBOX prognosis of death-censored graft survival. Mean (standard error) c-statistics were 0.81±0.03 for full iBOX, 0.80±0.03 for abbreviated iBOX, and 0.57±0.03 for BPAR. In calibration analyses, predicted graft loss events from both iBOX models were not significantly different from those observed. However, for BPAR, the predicted events were significantly (p<0.01) different (observed 64; predicted: 70 full iBOX; 76 abbreviated iBOX; 173 BPAR). IBOX at one-year post-transplant is superior to BPAR in the first year post-transplant in graft loss prognostic performance, providing valuable additional information facilitating the demonstration of superiority of novel immunosuppressive regimens.

16 June 2023 in Transplantation
Verified
Journal Article
Closed access
WFWilliam Fitzsimmons
William Fitzsimmons
MNMaarten Naesens
Maarten Naesens

10 July 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
LKLuke Kosinski
Luke Kosinski
EFEric Frey
Eric Frey
AKAmanda Klein
Amanda Klein
IOInish O'DOherty
Inish O'DOherty
KRKlaus Romero
Klaus Romero
T(Transplant Therapeutics Consortium (TTC)
Transplant Therapeutics Consortium (TTC)
Kidney transplantation is the preferred treatment for individuals with end‐stage kidney disease. From a modeling perspective, our understanding of kidney function trajectories after transplantation remains limited. Current modeling of kidney function post‐transplantation is focused on linear slopes or percent decline and often excludes the highly variable early timepoints post‐transplantation, where kidney function recovers and then stabilizes. Using estimated glomerular filtration rate (eGFR), a well‐known biomarker of kidney function, from an aggregated dataset of 4904 kidney transplant patients including both observational studies and clinical trials, we developed a longitudinal model of kidney function trajectories from time of transplant to 6 years post‐transplant. Our model is a nonlinear, mixed‐effects model built in NONMEM that captured both the recovery phase after kidney transplantation, where the graft recovers function, and the long‐term phase of stabilization and slow decline. Model fit was assessed using diagnostic plots and individual fits. Model performance, assessed via visual predictive checks, suggests accurate model predictions of eGFR at the median and lower 95% quantiles of eGFR, ranges which are of critical clinical importance for assessing loss of kidney function. Various clinically relevant covariates were also explored and found to improve the model. For example, transplant recipients of deceased donors recover function more slowly after transplantation and calcineurin inhibitor use promotes faster long‐term decay. Our work provides a generalizable, nonlinear model of kidney allograft function that will be useful for estimating eGFR up to 6 years post‐transplant in various clinically relevant populations.